Low-Dose Bromocriptine Therapy in Parkinson's Disease

Ronald Pfeiffer, Kathleen Wilken, Carolyn Glaeske, Agapito S. Lorenzo

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The efficacy of low-dose bromocriptine mesylate administration (20 mg daily or less) was evaluated in a double-blind study. Nine of 16 individuals receiving bromocriptine completed the 40-week study. Modest, but significant, improvement was derived from bromocriptine therapy. Improvement was most evident in tremor. Maximum improvement was achieved with doses between 7.5 and 15.0 mg daily, with some decline in efficacy as doses approached 20 mg. Adverse effects were common, but were generally mild in severity. Our results suggest that bromocriptine in low doses may be an effective adjunct to carbidopa and levodopa (Sinemet) in the treatment of Parkinson's disease.

Original languageEnglish (US)
Pages (from-to)586-588
Number of pages3
JournalArchives of Neurology
Volume42
Issue number6
DOIs
StatePublished - 1985
Externally publishedYes

Fingerprint

Bromocriptine
Parkinson Disease
Tremor
Therapeutics
Double-Blind Method
Dose
Therapy
Parkinson's Disease
levodopa drug combination carbidopa
Efficacy

ASJC Scopus subject areas

  • Arts and Humanities (miscellaneous)
  • Clinical Neurology
  • Neuroscience(all)

Cite this

Low-Dose Bromocriptine Therapy in Parkinson's Disease. / Pfeiffer, Ronald; Wilken, Kathleen; Glaeske, Carolyn; Lorenzo, Agapito S.

In: Archives of Neurology, Vol. 42, No. 6, 1985, p. 586-588.

Research output: Contribution to journalArticle

Pfeiffer, Ronald ; Wilken, Kathleen ; Glaeske, Carolyn ; Lorenzo, Agapito S. / Low-Dose Bromocriptine Therapy in Parkinson's Disease. In: Archives of Neurology. 1985 ; Vol. 42, No. 6. pp. 586-588.
@article{fb1e5d17863f4500856e35ababfac15a,
title = "Low-Dose Bromocriptine Therapy in Parkinson's Disease",
abstract = "The efficacy of low-dose bromocriptine mesylate administration (20 mg daily or less) was evaluated in a double-blind study. Nine of 16 individuals receiving bromocriptine completed the 40-week study. Modest, but significant, improvement was derived from bromocriptine therapy. Improvement was most evident in tremor. Maximum improvement was achieved with doses between 7.5 and 15.0 mg daily, with some decline in efficacy as doses approached 20 mg. Adverse effects were common, but were generally mild in severity. Our results suggest that bromocriptine in low doses may be an effective adjunct to carbidopa and levodopa (Sinemet) in the treatment of Parkinson's disease.",
author = "Ronald Pfeiffer and Kathleen Wilken and Carolyn Glaeske and Lorenzo, {Agapito S.}",
year = "1985",
doi = "10.1001/archneur.1985.04060060092015",
language = "English (US)",
volume = "42",
pages = "586--588",
journal = "Archives of Neurology",
issn = "0003-9942",
publisher = "American Medical Association",
number = "6",

}

TY - JOUR

T1 - Low-Dose Bromocriptine Therapy in Parkinson's Disease

AU - Pfeiffer, Ronald

AU - Wilken, Kathleen

AU - Glaeske, Carolyn

AU - Lorenzo, Agapito S.

PY - 1985

Y1 - 1985

N2 - The efficacy of low-dose bromocriptine mesylate administration (20 mg daily or less) was evaluated in a double-blind study. Nine of 16 individuals receiving bromocriptine completed the 40-week study. Modest, but significant, improvement was derived from bromocriptine therapy. Improvement was most evident in tremor. Maximum improvement was achieved with doses between 7.5 and 15.0 mg daily, with some decline in efficacy as doses approached 20 mg. Adverse effects were common, but were generally mild in severity. Our results suggest that bromocriptine in low doses may be an effective adjunct to carbidopa and levodopa (Sinemet) in the treatment of Parkinson's disease.

AB - The efficacy of low-dose bromocriptine mesylate administration (20 mg daily or less) was evaluated in a double-blind study. Nine of 16 individuals receiving bromocriptine completed the 40-week study. Modest, but significant, improvement was derived from bromocriptine therapy. Improvement was most evident in tremor. Maximum improvement was achieved with doses between 7.5 and 15.0 mg daily, with some decline in efficacy as doses approached 20 mg. Adverse effects were common, but were generally mild in severity. Our results suggest that bromocriptine in low doses may be an effective adjunct to carbidopa and levodopa (Sinemet) in the treatment of Parkinson's disease.

UR - http://www.scopus.com/inward/record.url?scp=0021827869&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021827869&partnerID=8YFLogxK

U2 - 10.1001/archneur.1985.04060060092015

DO - 10.1001/archneur.1985.04060060092015

M3 - Article

C2 - 4004603

AN - SCOPUS:0021827869

VL - 42

SP - 586

EP - 588

JO - Archives of Neurology

JF - Archives of Neurology

SN - 0003-9942

IS - 6

ER -